vs
EZCORP INC（EZPW）とPrestige Consumer Healthcare Inc.（PBH）の財務データ比較。上の社名をクリックして会社を切り替えられます
EZCORP INCの直近四半期売上が大きい（$382.0M vs $283.4M、Prestige Consumer Healthcare Inc.の約1.3倍）。Prestige Consumer Healthcare Inc.の純利益率が高く（16.5% vs 11.6%、差は4.9%）。EZCORP INCの前年同期比売上増加率が高い（19.3% vs -2.4%）。Prestige Consumer Healthcare Inc.の直近四半期フリーキャッシュフローが多い（$75.3M vs $31.7M）。過去8四半期でEZCORP INCの売上複合成長率が高い（15.6% vs 1.2%）
EZCORPはアメリカ合衆国テキサス州オースティンを本拠とする質屋運営企業です。アメリカ全土およびラテンアメリカで事業を展開しており、Cash America Internationalに次いでアメリカで2番目に規模の大きい質屋運営業者で、ナスダックに上場しています。
プレステージ・コンシューマー・ヘルスケア社はアメリカの企業で、一般用医薬品のヘルスケア製品および家庭用洗浄製品の販売・流通を手がけています。1996年にMedtech Products社、Prestige Brands International社、Spic and Span社の合併により設立され、本社はニューヨーク州タリータウン、バージニア州リンチバーグに製造工場を構えています。
EZPW vs PBH — 直接比較
損益計算書 — Q1 FY2026 vs Q3 FY2026
| 指標 | | |
|---|---|---|
| 売上 | $382.0M | $283.4M |
| 純利益 | $44.3M | $46.7M |
| 粗利率 | 58.4% | 55.5% |
| 営業利益率 | 15.9% | 29.1% |
| 純利益率 | 11.6% | 16.5% |
| 売上前年比 | 19.3% | -2.4% |
| 純利益前年比 | 42.8% | -23.5% |
| EPS（希薄化後） | $0.55 | $0.97 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $382.0M | $283.4M | ||
| Q3 25 | $336.8M | $274.1M | ||
| Q2 25 | $311.0M | $249.5M | ||
| Q1 25 | $306.3M | $296.5M | ||
| Q4 24 | $320.2M | $290.3M | ||
| Q3 24 | $294.6M | $283.8M | ||
| Q2 24 | $281.4M | $267.1M | ||
| Q1 24 | $285.6M | $277.0M |
| Q4 25 | $44.3M | $46.7M | ||
| Q3 25 | $26.7M | $42.2M | ||
| Q2 25 | $26.5M | $47.5M | ||
| Q1 25 | $25.4M | $50.1M | ||
| Q4 24 | $31.0M | $61.0M | ||
| Q3 24 | $15.2M | $54.4M | ||
| Q2 24 | $17.9M | $49.1M | ||
| Q1 24 | $21.5M | $49.5M |
| Q4 25 | 58.4% | 55.5% | ||
| Q3 25 | 59.0% | 55.3% | ||
| Q2 25 | 59.1% | 56.2% | ||
| Q1 25 | 58.3% | 57.3% | ||
| Q4 24 | 57.9% | 55.5% | ||
| Q3 24 | 59.5% | 55.5% | ||
| Q2 24 | 59.2% | 54.7% | ||
| Q1 24 | 58.7% | 54.8% |
| Q4 25 | 15.9% | 29.1% | ||
| Q3 25 | 11.0% | 29.1% | ||
| Q2 25 | 11.6% | 28.8% | ||
| Q1 25 | 11.2% | 29.8% | ||
| Q4 24 | 13.1% | 31.7% | ||
| Q3 24 | 8.8% | 29.7% | ||
| Q2 24 | 7.9% | 27.0% | ||
| Q1 24 | 9.6% | 29.7% |
| Q4 25 | 11.6% | 16.5% | ||
| Q3 25 | 7.9% | 15.4% | ||
| Q2 25 | 8.5% | 19.0% | ||
| Q1 25 | 8.3% | 16.9% | ||
| Q4 24 | 9.7% | 21.0% | ||
| Q3 24 | 5.2% | 19.2% | ||
| Q2 24 | 6.4% | 18.4% | ||
| Q1 24 | 7.5% | 17.9% |
| Q4 25 | $0.55 | $0.97 | ||
| Q3 25 | $0.35 | $0.86 | ||
| Q2 25 | $0.34 | $0.95 | ||
| Q1 25 | $0.33 | $1.00 | ||
| Q4 24 | $0.40 | $1.22 | ||
| Q3 24 | $0.20 | $1.09 | ||
| Q2 24 | $0.25 | $0.98 | ||
| Q1 24 | $0.29 | $0.98 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $465.9M | $62.4M |
| 総負債低いほど良い | $518.6M | $1.0B |
| 株主資本純資産 | $1.1B | $1.8B |
| 総資産 | $2.0B | $3.5B |
| 負債/資本比率低いほどレバレッジが低い | 0.48× | 0.56× |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $465.9M | $62.4M | ||
| Q3 25 | $469.5M | $119.1M | ||
| Q2 25 | $472.1M | $139.5M | ||
| Q1 25 | $505.2M | $97.9M | ||
| Q4 24 | $174.5M | $50.9M | ||
| Q3 24 | $170.5M | $51.5M | ||
| Q2 24 | $218.0M | $34.3M | ||
| Q1 24 | $229.1M | $46.5M |
| Q4 25 | $518.6M | $1.0B | ||
| Q3 25 | $518.1M | $993.1M | ||
| Q2 25 | $517.6M | $992.7M | ||
| Q1 25 | $620.5M | $992.4M | ||
| Q4 24 | $327.7M | $992.0M | ||
| Q3 24 | $327.3M | $1.1B | ||
| Q2 24 | $361.3M | $1.1B | ||
| Q1 24 | $360.9M | $1.1B |
| Q4 25 | $1.1B | $1.8B | ||
| Q3 25 | $1.0B | $1.8B | ||
| Q2 25 | $990.1M | $1.9B | ||
| Q1 25 | $851.6M | $1.8B | ||
| Q4 24 | $823.9M | $1.8B | ||
| Q3 24 | $804.6M | $1.7B | ||
| Q2 24 | $801.5M | $1.7B | ||
| Q1 24 | $800.4M | $1.7B |
| Q4 25 | $2.0B | $3.5B | ||
| Q3 25 | $2.0B | $3.4B | ||
| Q2 25 | $1.9B | $3.4B | ||
| Q1 25 | $1.8B | $3.4B | ||
| Q4 24 | $1.5B | $3.3B | ||
| Q3 24 | $1.5B | $3.3B | ||
| Q2 24 | $1.5B | $3.3B | ||
| Q1 24 | $1.5B | $3.3B |
| Q4 25 | 0.48× | 0.56× | ||
| Q3 25 | 0.51× | 0.54× | ||
| Q2 25 | 0.52× | 0.54× | ||
| Q1 25 | 0.73× | 0.54× | ||
| Q4 24 | 0.40× | 0.55× | ||
| Q3 24 | 0.41× | 0.61× | ||
| Q2 24 | 0.45× | 0.65× | ||
| Q1 24 | 0.45× | 0.68× |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $39.1M | $78.3M |
| フリーキャッシュフロー営業CF - 設備投資 | $31.7M | $75.3M |
| FCFマージンFCF / 売上 | 8.3% | 26.6% |
| 設備投資強度設備投資 / 売上 | 2.0% | 1.1% |
| キャッシュ転換率営業CF / 純利益 | 0.88× | 1.68× |
| 直近12ヶ月FCF直近4四半期 | $121.7M | $267.2M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $39.1M | $78.3M | ||
| Q3 25 | $51.3M | $57.5M | ||
| Q2 25 | $34.8M | $79.0M | ||
| Q1 25 | $36.9M | $61.8M | ||
| Q4 24 | $26.0M | $65.1M | ||
| Q3 24 | $43.3M | $69.8M | ||
| Q2 24 | $33.7M | $54.8M | ||
| Q1 24 | $15.1M | $66.9M |
| Q4 25 | $31.7M | $75.3M | ||
| Q3 25 | $35.7M | $55.4M | ||
| Q2 25 | $25.7M | $78.2M | ||
| Q1 25 | $28.6M | $58.4M | ||
| Q4 24 | $20.4M | $63.5M | ||
| Q3 24 | $24.4M | $67.8M | ||
| Q2 24 | $30.5M | $53.6M | ||
| Q1 24 | $8.6M | $63.8M |
| Q4 25 | 8.3% | 26.6% | ||
| Q3 25 | 10.6% | 20.2% | ||
| Q2 25 | 8.3% | 31.3% | ||
| Q1 25 | 9.3% | 19.7% | ||
| Q4 24 | 6.4% | 21.9% | ||
| Q3 24 | 8.3% | 23.9% | ||
| Q2 24 | 10.8% | 20.1% | ||
| Q1 24 | 3.0% | 23.0% |
| Q4 25 | 2.0% | 1.1% | ||
| Q3 25 | 4.6% | 0.8% | ||
| Q2 25 | 2.9% | 0.3% | ||
| Q1 25 | 2.7% | 1.2% | ||
| Q4 24 | 1.8% | 0.5% | ||
| Q3 24 | 6.4% | 0.7% | ||
| Q2 24 | 1.1% | 0.4% | ||
| Q1 24 | 2.3% | 1.1% |
| Q4 25 | 0.88× | 1.68× | ||
| Q3 25 | 1.92× | 1.36× | ||
| Q2 25 | 1.31× | 1.66× | ||
| Q1 25 | 1.45× | 1.23× | ||
| Q4 24 | 0.84× | 1.07× | ||
| Q3 24 | 2.85× | 1.28× | ||
| Q2 24 | 1.88× | 1.12× | ||
| Q1 24 | 0.70× | 1.35× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
EZPW
| Merchandise | $210.1M | 55% |
| Pawn Service | $131.9M | 35% |
| Jewelry Scrap | $39.9M | 10% |
PBH
| Womens Health | $51.8M | 18% |
| International OTC Healthcare | $47.7M | 17% |
| Gastrointestinal | $44.2M | 16% |
| Eye And Ear Care | $35.2M | 12% |
| Dermatologicals | $27.6M | 10% |
| Analgesics | $26.7M | 9% |
| Oral Care | $23.5M | 8% |
| Cough And Cold | $23.0M | 8% |
| Other Otc | $3.6M | 1% |
